Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 crawled date : 2021 - 06 - 11 save search
BioVie Announces Closing of Acquisition of BioPharma Assets from Privately Held NeurMedixCompany Expects to Commence Enrollment in Pivotal Phase 3 Alzheimer’s Trial in Mid-2021
Published: 2021-06-11 (Crawled : 13:00) - biospace.com/
BIVI | $0.4929 2.01% 1.97% 690K
|
Health Technology
|
| O: 0.87%
H: 21.8%
C: 20.6%
alzheimer biopharma acquisition mid-2021 phase 3 trial enroll alzheimer’s alzheimer's
TG Therapeutics Announces Data from a Phase 1 Study Evaluating TG-1701 as a Monotherapy and as a Triple Combination with Ublituximab and UKONIQ® at the 2021 European Hematology Association Virtual Congress
Published: 2021-06-11 (Crawled : 12:00) - biospace.com/
TGTX | $14.25 1.06% 1.05% 3.2M
|
Health Technology
|
| O: -0.24%
H: 0.63%
C: -0.29%
europe phase 1 therapy phase 3
Forma Therapeutics Presents New Phase 1 Data on Etavopivat (formerly referred to as FT-4202) at 26th European Hematology Association Congress
Published: 2021-06-11 (Crawled : 12:00) - biospace.com/
FMTX | $20.01 -0.15%
|
Health Technology
|
| O: -6.42%
H: 0.0%
C: -12.91%
europe phase 1 phase 3 phase 2
Curis Announces Positive Updated Data from Ongoing Phase 1/2 Study of CA-4948 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes
Published: 2021-06-11 (Crawled : 12:00) - biospace.com/
CRIS | $14.73 -0.81% -0.81% 5.8K
|
Health Technology
|
| O: -23.82%
H: 0.41%
C: -17.08%
myeloid leukemia ongoing phase 1 positive therapy leukemia phase 3 phase 2 syndros ca-4948 acute myeloid leukemia
Editas Medicine Presents Preclinical Data Supporting the Initiation of the EDIT-301 Phase 1/2 RUBY Clinical Trial for the Treatment of Sickle Cell Disease at the European Hematology Association Congress
Published: 2021-06-11 (Crawled : 11:00) - globenewswire.com
EDIT | News | $5.465 -2.41% -2.47% 1.6M
|
Health Technology
|
| O: 1.73%
H: 1.89%
C: -0.32%
disease treatment europe phase 1 trial phase 3 preclinical pre-clinical
Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 CD20-Targeted CAR T in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
Published: 2021-06-11 (Crawled : 11:00) - globenewswire.com
MBIO | $0.3355 -1.32% -1.34% 120K
|
Health Technology
|
| O: 4.99%
H: 1.5%
C: -5.25%
FBIO | $1.79 2.29% 2.23% 190K
|
Health Technology
|
| O: 3.49%
H: 0.9%
C: 0.9%
phase 1 leukemia phase 3 car-t t-cell
Novan Reports Positive Topline Results from Pivotal Phase 3 Trial of SB206 in Patients with Molluscum Contagiosum
Published: 2021-06-11 (Crawled : 11:00) - globenewswire.com
NOVN | $0.0941 -24.84% -32.91% 7.2M
|
Health Technology
|
| O: 58.85%
H: 30.08%
C: 2.23%
molluscum positive results topline phase 3 trial
Agios Announces Updated Data from ACTIVATE and ACTIVATE-T Phase 3 Studies of Mitapivat in Pyruvate Kinase (PK) Deficiency at the European Hematology Association Virtual Congress
Published: 2021-06-11 (Crawled : 08:00) - globenewswire.com
AGIO | $31.82 5.33% 5.06% 1.2M
|
Health Technology
|
| O: 0.57%
H: 0.0%
C: -3.51%
europe phase 3
Celyad Oncology Presents Preliminary Data from Phase 1 IMMUNICY-1 Trial of shRNA-based Allogeneic CAR T Candidate CYAD-211 in Relapsed/Refractory Multiple Myeloma at the European Hematology Association Virtual Congress
Published: 2021-06-11 (Crawled : 07:00) - globenewswire.com
CYAD | $0.47 -12.49% 49K
|
Health Technology
|
| O: -0.83%
H: 7.56%
C: -2.02%
europe phase 1 trial phase 3 car-t
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.